LAB International to Hold Fourth Quarter and Fiscal 2006 Conference Call and Webcast

MONTREAL, March 20 /PRNewswire-FirstCall/ - LAB International Inc. ("LAB"), a drug development company focused on developing therapies for the inhalation and pain markets, today announced that it will report financial results for the fourth quarter and fiscal 2006 ended December 31, 2006 on Monday March 26, 2007.

LAB will host a conference call at 10:00 a.m., on Monday March 26, 2007. Interested parties may also access the conference call by webcast at www.labinc.ca.

The telephone number to access the conference call is 1-800-591-7539. A replay of the call will be available until Monday April 2, 2007. The telephone numbers to access the replay are 416-640-1917 and 1-877-289-8525 with code number 21224056#.

About LAB International

LAB International is an integrated drug development company focused on the growing multi-billion dollar inhalation market. Its lead product, for the treatment of breakthrough cancer pain, is a fast-acting Fentanyl formulation delivered using the Company's TAIFUN(R) dry powder inhaler platform. Its pipeline also includes therapeutics for asthma, COPD, and growth hormone deficiencies.

LAB's common shares trade on The Toronto Stock Exchange ("TSX") under the symbol "LAB", on the Frankfurt Regulated Unofficial Market under the symbol "LD9.F" and on XETRA under the symbol "LD9.DE" with 82.3 million shares outstanding.

This news release contains certain forward-looking statements that reflect the current views and/or expectations of LAB International Inc. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.

CONTACT: visit LAB's website at www.labinc.ca, or contact: FredericDumais, Vice-President, Investor Relations, (514) 315-3330 ext. 106, Fax:(514) 315-3325, dumaisf@labinc.ca